{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:32:41Z","timestamp":1779114761458,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r\/r ALCL, however, this is not an effective treatment for all ALK+ALCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>Herein, we report a patient with relapsed\/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed\/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1346001","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T04:53:10Z","timestamp":1707108790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed\/refractory ALK+ ALCL"],"prefix":"10.3389","volume":"15","author":[{"given":"Wanying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the groupe d'etude des lymphomes de l'adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213512","article-title":"Alk-positive anaplastic large-cell lymphoma in adults: An individual patient data pooled analysis of 263 patients","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and asct on survival among patients aged <65 years with stage ii to iv ptcl: A population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for cd30-positive peripheral t-cell lymphoma (echelon-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The echelon-2 trial: 5-year results of a randomized, phase iii study of brentuximab vedotin with chemotherapy for cd30-positive peripheral t-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with alk+ alcl: Results of cog trial anhl12p1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29602","article-title":"Fda approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"69","author":"Merino","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007538","article-title":"A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed\/refractory alk+ lymphomas","volume":"7","author":"Rindone","year":"2023","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in alk-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: Results of the french acs\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting alk with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A children\u2019s oncology group study","volume":"35","author":"Yael","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma","volume":"126","author":"Richly","year":"2015","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase ii trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory hodgkin's lymphoma and anaplastic large-cell lymphoma: A multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171355","article-title":"Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed\/refractory systemic anaplastic large cell lymphoma","volume":"102","author":"Broccoli","year":"2017","journal-title":"Haematologica."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory alk+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: A case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral t cell lymphoma: A multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0413","article-title":"The combination of chidamide with the choep regimen in previously untreated patients with peripheral t-cell lymphoma: A prospective, multicenter, single arm, phase 1b\/2 study","volume":"18","author":"Zhang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral t-cell lymphoma: A non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral t-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature t-cell non-hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral t-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-022-00323-9","article-title":"Autologous stem cell transplantation in tandem with anti-cd30 car t-cell infusion in relapsed\/refractory cd30(+) lymphoma","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T04:53:13Z","timestamp":1707108793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1346001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2024.1346001"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1346001","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"article-number":"1346001"}}